Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

被引：0

作者：

Joyce O’Shaughnessy

Adam Brufsky

Hope S. Rugo

Sara M. Tolaney

Kevin Punie

Sagar Sardesai

Erika Hamilton

Delphine Loirat

Tiffany Traina

Roberto Leon-Ferre

Sara A. Hurvitz

Kevin Kalinsky

Aditya Bardia

Stephanie Henry

Ingrid Mayer

Yanni Zhu

See Phan

Javier Cortés

机构：

[1] Texas Oncology-Baylor Charles A. Sammons Cancer Center,Medical Oncology

[2] University of Pittsburgh Medical Center,Magee

[3] University of California San Francisco Helen Diller Family Comprehensive Cancer Center,Womens Hospital and the Hillman Cancer Center

[4] Dana-Farber Cancer Institute,Department of Medicine

[5] Leuven Cancer Institute,Medical Oncology

[6] University Hospitals Leuven,Department of General Medical Oncology and Multidisciplinary Breast Centre

[7] The Ohio State University Comprehensive Cancer Center,Medical Oncology Department and D3i

[8] Sarah Cannon Research Institute/Tennessee Oncology,Department of Oncology

[9] Institut Curie,Medical Oncology

[10] Memorial Sloan Kettering Cancer Center,Department of Hematology/Oncology

[11] Mayo Clinic,Department of Oncology

[12] University of California,Hematology, Radiotherapy, and Nuclear Medicine

[13] Los Angeles,Breast Cancer Program, Division of Hematology/Oncology

[14] Jonsson Comprehensive Cancer Center,Department of Biostatistics

[15] Columbia University Irving Medical Center,Department of Clinical Development

[16] Massachusetts General Hospital Cancer Center,International Breast Cancer Center

[17] Harvard Medical School,undefined

[18] CHU UCL Namur,undefined

[19] Vanderbilt-Ingram Cancer Center,undefined

[20] Gilead Sciences,undefined

[21] Inc.,undefined

[22] Gilead Sciences,undefined

[23] Inc.,undefined

[24] Quironsalud Group,undefined

[25] Winship Cancer Institute,undefined

[26] Emory University,undefined

来源：

Breast Cancer Research and Treatment | 2022年 / 195卷

关键词：

Sacituzumab govitecan; Antibody–drug conjugate; Cyclin-dependent kinase inhibitor;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：127 / 139

页数：12

共 50 条

[21] Sacituzumab govitecan-a new therapy for patients with triple-negative breast cancer
Pogoda, Katarzyna
Jagiello-Gruszfeld, Agnieszka
Niwinska, Anna
Nowecki, Zbigniew
ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (01): : 43 - 49
[22] Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom
Hanna, Daire
Merrick, Sophie
Ghose, Aruni
Devlin, Michael John
Yang, Dorothy D.
Phillips, Edward
Okines, Alicia
Chopra, Neha
Papadimatraki, Elisavet
Ross, Kirsty
Macpherson, Iain
Boh, Zhuang Y.
Michie, Caroline O.
Swampillai, Angela
Gupta, Sunnia
Robinson, Tim
Germain, Lewis
Twelves, Chris
Atkinson, Charlotte
Konstantis, Apostolos
Riddle, Pippa
Cresti, Nicola
Naik, Jay D.
Borley, Annabel
Guppy, Amy
Schmid, Peter
Phillips, Melissa
BRITISH JOURNAL OF CANCER, 2024, 130 (12) : 1916 - 1920
[23] Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
Maltoni, Roberta
Bravaccini, Sara
ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (07)
[24] Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer
Weiss, Jennifer
Glode, Ashley
Messersmith, Wells A.
Diamond, Jennifer
EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (08) : 673 - 679
[25] Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study
Carrion-Madronal, Isabel Maria
Diaz-Acedo, Rocio
Lora-Escobar, Santiago Jose
Naranjo-Llamas, Eloisa
Jaramillo-Ruiz, Didiana
Artacho-Criado, Silvia
Prado-Mel, Elena
FUTURE ONCOLOGY, 2024, 20 (33) : 2565 - 2572
[26] Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).
Carey, Lisa A.
Loirat, Delphine
Punie, Kevin
Bardia, Aditya
Dieras, Veronique
Dalenc, Florence
Diamond, Jennifer Robinson
Fontaine, Christel
Wang, Grace
Rugo, Hope S.
Hurvitz, Sara A.
Kalinsky, Kevin
O'Shaughnessy, Joyce
Loibl, Sibylle
Gianni, Luca
Piccart-Gebhart, Martine J.
Hong, Quan
Olivo, Martin Sebastian
Itri, Loretta
Cortes, Javier
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[27] Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
Hegewisch-Becker, S.
Oliveira, M.
Traina, T.
Tolaney, S. M.
Loirat, D.
Punie, K.
Hurvitz, S. A.
Lynce, F.
Hamilton, E.
Nanda, R.
Hart, L.
Richards, P.
Malik, Z.
Rugo, H. S.
Dieras, V
Bardia, A.
Hong, Q.
Phan, S.
Itri, L. M.
Loibl, S.
Kalinsky, K.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 242 - 242
[28] Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer (vol 10, 33, 2024)
Hurvitz, Sara A.
Bardia, Aditya
Punie, Kevin
Kalinsky, Kevin
Carey, Lisa A.
Rugo, Hope S.
Dieras, Veronique
Phan, See
Delaney, Rosemary
Zhu, Yanni
Tolaney, Sara M.
NPJ BREAST CANCER, 2024, 10 (01)
[29] Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).
Kalinsky, Kevin
Oliveira, Mafalda
Traina, Tiffany A.
Tolaney, Sara M.
Loirat, Delphine
Punie, Kevin
Hurvitz, Sara A.
Lynce, Filipa
Hamilton, Erika P.
Nanda, Rita
Hart, Lowell L.
Richards, Paul D.
Malik, Zulfiqar A.
Rugo, Hope S.
Dieras, Veronique
Bardia, Aditya
Hong, Quan
Olivo, Martin Sebastian
Itri, Loretta
Loibl, Sibylle
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[30] Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase III ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC)
O'Shaughnessy, J.
Brufsky, A.
Rugo, H. S.
Tolaney, S. M.
Diab, S.
Punie, K.
Sardesai, S.
Hamilton, E.
Loirat, D.
Traina, T. A.
Leon-Ferre, R.
Hurvitz, S. A.
Kalinsky, K.
Bardia, A.
Henry, S.
Mayer, I.
Hong, Q.
Phan, S.
Cortes, J.
ANNALS OF ONCOLOGY, 2021, 32 : S473 - S474

← 1 2 3 4 5 →